Special Issue "Vaccine Adjuvants"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (15 December 2013)

Special Issue Editor

Guest Editor
Dr. Edward Lavelle
Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland
Website: http://people.tcd.ie/lavellee
E-Mail: lavellee@tcd.ie
Interests: adjuvant; vaccine; mucosal; inflammasome; particulate adjuvant; innate immunity; nanoparticle

Special Issue Information

Dear Colleagues,

The field of vaccine adjuvant research is very dynamic and is expanding across both academic and industrial sectors. In tandem with the increased scope of vaccination beyond traditional prophylactic approaches, novel therapeutic vaccine strategies for chronic infection diseases, cancer and other indications demand the identification of new and improved targeted adjuvant strategies. Vaccine adjuvants can serve a range of functions including amplifying, directing and regulating immune responses but also protecting antigens, achieving multimeric antigen presentation and controlling antigen release. This issue will address the potential of novel adjuvant strategies to modulate innate and adaptive immune responses in order to facilitate the development of improved prophylactic or therapeutic vaccines. There is a specific focus on particulate vaccine adjuvants, however, contributions on other established and experimental adjuvants or their modes of action are welcome.

Dr. Edward Lavelle
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • adjuvant
  • vaccine
  • mucosal
  • inflammasome
  • particulate adjuvant
  • innate immunity
  • nanoparticle

Published Papers (7 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-7
p. 797-831
by
Vaccines 2014, 2(4), 797-831; doi:10.3390/vaccines2040797
Received: 4 May 2014; in revised form: 19 September 2014 / Accepted: 24 September 2014 / Published: 14 November 2014
Show/Hide Abstract | PDF Full-text (906 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
p. 500-514
by , , ,  and
Vaccines 2014, 2(3), 500-514; doi:10.3390/vaccines2030500
Received: 17 February 2014; in revised form: 2 June 2014 / Accepted: 4 June 2014 / Published: 26 June 2014
Show/Hide Abstract | PDF Full-text (1029 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
p. 323-353
by  and
Vaccines 2014, 2(2), 323-353; doi:10.3390/vaccines2020323
Received: 11 February 2014; in revised form: 27 March 2014 / Accepted: 28 March 2014 / Published: 25 April 2014
Show/Hide Abstract | PDF Full-text (887 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
p. 297-322
by , , , ,  and
Vaccines 2014, 2(2), 297-322; doi:10.3390/vaccines2020297
Received: 3 January 2014; in revised form: 22 March 2014 / Accepted: 28 March 2014 / Published: 14 April 2014
Show/Hide Abstract | Cited by 1 | PDF Full-text (694 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
p. 252-296
by  and
Vaccines 2014, 2(2), 252-296; doi:10.3390/vaccines2020252
Received: 27 December 2013; in revised form: 20 March 2014 / Accepted: 28 March 2014 / Published: 10 April 2014
Show/Hide Abstract | PDF Full-text (530 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
p. 216-227
by , , ,  and
Vaccines 2014, 2(2), 216-227; doi:10.3390/vaccines2020216
Received: 5 December 2013; in revised form: 25 February 2014 / Accepted: 10 March 2014 / Published: 25 March 2014
Show/Hide Abstract | PDF Full-text (839 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
abstract graphic
p. 228-251
by , , , , ,  and
Vaccines 2014, 2(2), 228-251; doi:10.3390/vaccines2020228
Received: 16 December 2013; in revised form: 21 February 2014 / Accepted: 13 March 2014 / Published: 25 March 2014
Show/Hide Abstract | Cited by 2 | PDF Full-text (574 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Vaccine Adjuvants)
Select/unselect all
Displaying article 1-7
Select articles Export citation of selected articles as:

Last update: 30 April 2013

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert